Role of FDA’s Office of Regulatory Affairs (ORA)

Understanding the Role of the FDA’s Office of Regulatory Affairs (ORA) in GMP Oversight

The Office of Regulatory Affairs (ORA) is the field operations arm of the US Food and Drug Administration (FDA), responsible for conducting inspections, enforcing compliance, and protecting public health through regulatory oversight. In the context of pharmaceuticals, the ORA plays a central role in evaluating GMP adherence, collecting evidence, and recommending enforcement actions. This article provides an in-depth look at the role of the FDA’s ORA in Good Manufacturing Practice (GMP) inspection programs and its collaborative efforts with FDA centers such as CDER.

Overview of ORA’s Mission and Structure:

ORA serves as the FDA’s lead office for all field operations and enforcement
It employs over 5,000 staff, including more than 2,000 investigators and inspectors
Operates across US districts and internationally with foreign inspectional units
Works across all regulated products: drugs, biologics, devices, food, tobacco, and cosmetics

Key Functions of ORA in the Pharmaceutical Sector:

1. GMP Inspections of Domestic and Foreign Facilities

Conducts routine surveillance, pre-approval, and for-cause inspections
Assesses compliance with 21 CFR Parts 210 and 211
Issues Form 483s to document inspectional observations
Evaluates manufacturing, quality control, stability programs, and data integrity

Also Read: Strategic Importance of WHO PQP for Global Procurement

2. Collaboration with CDER and

Other Centers

CDER (Center for Drug Evaluation and Research) identifies facilities for inspection
ORA executes field inspections and sends reports (EIRs) to CDER for compliance decisions
Coordinated response for Warning Letters, Import Alerts, and application holds

3. Enforcement and Regulatory Action

ORA recommends enforcement actions based on inspection findings
Supports criminal investigations, injunctions, and seizures through FDA’s Office of Chief Counsel
Maintains a field presence to follow up on CAPAs, recalls, and compliance verification

4. Import Operations and Border Surveillance

Screen and inspect imported pharmaceutical products at US ports of entry
Use the PREDICT system to flag high-risk shipments
Support detention without physical examination for firms on Import Alert

Organizational Units within ORA:

Office of Pharmaceutical Quality Operations (OPQO): Manages drug inspection programs
Office of Enforcement and Import Operations (OEIO): Handles compliance actions and border inspections
Office of Regulatory Science (ORS): Provides lab support for field investigations
ORA International Affairs: Coordinates foreign inspections and regulatory collaboration

ORA’s GMP Inspection Lifecycle:

Site selection by CDER based on risk-based model
Inspection planning and pre-inspection briefing
On-site inspection by trained ORA investigators
Issuance of Form 483 (if needed) and closeout discussion
Submission of Establishment Inspection Report (EIR)
CDER review of EIR and classification (NAI, VAI, OAI)

What ORA Investigators Focus On During GMP Inspections:

Batch records, deviations, and OOS investigations
Data integrity controls, audit trails, and electronic systems (21 CFR Part 11)
SOP implementation and compliance with validated processes
Cleaning validation, environmental monitoring, and stability testing
QA oversight and CAPA management systems

Training and Qualification of ORA Investigators:

Complete ORA’s Basic Drug School and advanced GMP training modules
Undergo mentorship programs and perform mock inspections
Receive annual refresher courses in ICH, PIC/S, and FDA guidance

Global Engagement by ORA:

Conducts foreign inspections under FDA’s Global Inspection Program
Participates in harmonization efforts with EMA, WHO, MHRA, and TGA
Supports Mutual Recognition Agreements (MRAs) with trusted regulatory authorities

Recent ORA Initiatives and Focus Areas:

Data integrity enforcement and audit trail reviews
Risk-based inspection models for domestic and foreign sites
Advanced analytical and laboratory support through ORA science labs
Use of remote regulatory assessments (RRAs) and digital tools

How Manufacturers Can Align with ORA Expectations:

Maintain inspection readiness with updated documentation
Conduct internal audits simulating ORA inspection structure
Review Form 483 trends to proactively fix systemic gaps
Ensure QA oversight and leadership accountability in GMP matters
Stay informed about changes to inspection policies and risk models

Conclusion:

The FDA’s Office of Regulatory Affairs (ORA) is a central pillar in safeguarding drug quality through rigorous GMP oversight. With responsibilities ranging from inspection execution and evidence collection to import surveillance and enforcement action, ORA ensures that pharmaceutical manufacturers remain accountable and compliant. Understanding how ORA operates—and preparing accordingly—can significantly reduce compliance risks, foster transparency, and strengthen regulatory trust across global markets.